Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.

Obesity and type 2 diabetes mellitus (T2DM) frequently coexist and markedly increase cardiometabolic risk. Orforglipron is a novel oral glucagon-like peptide-1 receptor agonist developed to improve adherence compared with injectable therapies. We performed a systematic review and meta-analysis to evaluate its efficacy and safety.